UroToday - European Urology

Botulinum Toxin—New Mechanisms, New Therapeutic Directions?
Thursday, 06 April 2006
In 2002 the International Continence Society (ICS) published an updated standardisation report on the terminology that describes lower urinary tract function [1]. In this report the overactive bladder syndrome (OABS) or urgency frequency syndrome was defined as ‘‘urgency, with or without urge incontinence, usually with frequency and nocturia’’; urgency was defined as ‘‘the complaint of a sudden compelling desire to pass urine which is difficult to defer’’. Urgency is the pivotal symptom in OABS and drives the other symptoms inherent in OABS, including frequency, nocturia, and urgency incontinence [2]; but is difficult to measure and may arise as the consequence of multiple pathophysiologies. Painful bladder syndrome/interstitial cystitis (PBS/IC), however, encompasses the same spectrum of symptoms but with the additional and pre-eminent triggering symptom of pain.
read more

Tachykinins: Role in Detrusor Overactivity?
Wednesday, 01 March 2006
The nerves of the lower urinary tract synthetize, store, and release many neuropeptides, including tachykinins, i.e., substance P (SP), neurokinin A (NKA), and neurokinin B (NKB) [1]. It is generally accepted that tachykinins have an important role in afferent signaling from the bladder, and that they may be involved in different pathologies in the lower urinary tract.
read more

Effect of an ATP-Sensitive Potassium Channel Opener in Subjects with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Study (ZD0947IL/0004)
Saturday, 06 May 2006
Objective: Improvements over existing treatment standards in overactive bladder (OAB) may only be possible through the development of drugs acting via non-cholinergic pathways. This is the first clinical study to be reported in full for the use of a potassium channel opener in OAB.
read more

European Urology - Effect of Intravesical Resiniferatoxin (RTX) on Lower Urinary Tract Symptoms, Urodynamic Parameters, and Quality of Life of Patients with Urodynamic Increased Bladder Sensation
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1299-1305 (December 2006) Abstract - Objectives: Intravesical resiniferatoxin (RTX) has been used with variable efficacy in the treatment of detrusor overactivity (DO).
read more

European Urology - Histologic Features in the Urinary Bladder Wall Affected from Neurogenic Overactivity—A Comparison of Inflammation, Oedema and Fibrosis With and Without Injection of Botulinum Toxin Type A
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1058-1064 (November 2006) Abstract - Objectives: To study histological features and morphological differences in bladder wall specimen from patients with and without botulinum toxin A injections and to compare those issues in responders and non-responders to the toxin therapy.
read more

Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity
Monday, 03 April 2006
Background: Treatment of human bladder overactivity with intradetrusor Botulinum-A neurotoxin (BoNT/A) injections temporarily blocks the presynaptic release of acetylcholine from the parasympathetic innervation and produces a paralysis of the detrusor smooth muscle. The efficacy of the treatment exceeds that expected from simple detrusor muscle paralysis, however, and its effect of reducing urgency is greatly welcomed by patients.
read more

European Urology - The Current and Future Burden and Cost of Overactive Bladder in Five European Countries
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1050-1057 (November 2006) Abstract - Objective: To estimate and compare the current and future direct cost of overactive bladder (OAB) to the health care systems of five European countries.
read more

European Urology - New Frontiers in Intravesical Therapies and Drug Delivery
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1183-1193 (December 2006) Abstract - Objectives: The intravesical route permits site-specific delivery of drugs with a reduced side-effect profile as compared to oral delivery systems, either by avoiding first-pass metabolism or by obtaining a local effect.
read more

European Urology - Botulinum Toxin Injections for Neurogenic and Idiopathic Detrusor Overactivity: A Critical Analysis of Results
Thursday, 21 September 2006
Volume 50, Issue 4, Pages 684-710 (October 2006) Abstract - Objective:In recent years there has been an increasing use of the botulinum neurotoxins for the management of conditions characterised by detrusor overactivity. Early studies showed promising results in an area where few options previously existed between pharmacotherapy and surgery.
read more

browse categories

Member's Section

Quick Search

UroToday International Journal